Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

To main content To sitemap To news Check availability details

Biological drugs

The research program for protein research, method development and production of biological drugs offered Vinnova opportunity to seek funding for the project that contribute to better health.

This web page has been machine translated. If there are any uncertainties, please refer to the Swedish text.

Background to the investment

The Government has commissioned Vinnova and the Swedish Research Council to jointly design a national programme for protein research, method development and production of biological drugs.

The program is part of the government's strategic effort on health (life science) which together will contribute to better health, to meet societal challenges, strengthen Sweden's position as a leading country in research and development and increase Sweden's competitiveness in an international perspective.

The program refers to both research on proteins for future biological drugs and the development of more efficient methods for next-generation drug production.

The program runs from 2016 to 2023 and covers SEK 320 million.

See previous offers for funding

Funded project

Here you can read more about the project that Vinnova has previously financed in biological drugs.

Project title Coordinator Grant Status Reference number
LaScaRNA - Large Scale Production of mRNA for Therapeutic Applications Region Stockholm SEK 5 000 000 Ongoing 2021-04499
Amniotic derived cell based therapy for restoration of damaged discarded organs for clinical transplantation Region Skåne SEK 4 787 500 Ongoing 2021-04489
Large scale production of human hepatocytes KUNGLIGA TEKNISKA HÖGSKOLAN SEK 4 916 000 Completed 2017-02984
ESCAPE Cancer - Engineered SCAffold Proteins Engaged for CANCER therapy Uppsala universitet SEK 4 972 200 Completed 2016-04060
Continuous directed evolution of cell permeable peptides for drug leads and drug delivery Chalmers Tekniska Högskola AB SEK 6 560 170 Completed 2019-00105
Pancreatic tissue-precursors assembled by bioactive silk KUNGLIGA TEKNISKA HÖGSKOLAN SEK 4 997 827 Completed 2016-04109
Improved cost efficacy and safety for CNS immunotherapy Uppsala universitet SEK 5 000 000 Completed 2016-04050
Novel technology for the purification of biopharmaceuticals LAB-ON-A-BEAD AB SEK 1 648 244 Completed 2016-04152
Development of an inhaled biological agent for COVID-19 Treat4Life AB SEK 5 000 000 Completed 2021-04500
Process development for CAR-T cell manufacturing Elicera Therapeutics AB SEK 4 993 162 Completed 2021-04488
Development of bispecific antibodies against leukemia and hematopoetic stem cells Karolinska Universitetssjukhuset SEK 4 840 000 Completed 2017-02978
CellNova - a VINNOVA centre for development and production of next generation biological drugs Kungliga Tekniska Högskolan SEK 44 000 000 Completed 2017-02105
Development and formulation centre for next generation biologics RISE Research Institutes of Sweden AB SEK 16 000 000 Completed 2017-02155
Centre for Advanced Medical Products Umeå universitet SEK 52 000 000 Completed 2017-02130
Novel Sensors for Online Monitoring of Continuous Biological Production Processes Linköpings universitet SEK 4 770 597 Completed 2016-04120
Stabilised and modular protein drugs Karolinska Institutet SEK 2 494 400 Completed 2016-04145
GMP NEURAL PROGENITOR CELLS FOR TRANSPLANTATION INTO SPINAL CORD INJURIES Karolinska Institutet SEK 4 994 383 Completed 2016-04134
A new class of functional antibodies addressing TRP ion channels for pain and cancer therapy Oblique Therapeutics AB SEK 1 399 830 Completed 2016-04093
Swedish egg antibodies for severe clinical infections (SWEAsci) Uppsala universitet SEK 4 959 820 Completed 2016-04083
EFFICIENT PRODUCTION AND DEVELOPMENT OF NOVEL BIOLOGICS INSPIRED BY HOW SPIDERS MAKE SILK Karolinska Institutet SEK 5 000 000 Completed 2016-04059
Integrated Continuous Downstream Processes for Next-generation of Biologics Lunds universitet SEK 5 000 000 Completed 2016-04048
Novel biological treatment for diabetic foot ulcers Omnio AB SEK 4 953 900 Completed 2021-04496
Clinical evaluation of XSTEM, a novel stem cell therapy for treatment of difficult-to-heal venous leg ulcers Xintela AB SEK 4 883 500 Completed 2021-04494
NucleoDry: Development of a platform for dry mRNA vaccines and lipid nanoformulations RISE Research Institutes of Sweden AB SEK 4 994 980 Completed 2021-04493
Platform for the personalization of xenogeneic and 3D printed tissue scaffolds RISE Research Institutes of Sweden AB SEK 4 921 746 Completed 2021-04484
Odling av stamceller på specialdesignad nanofiberbaser matris för tillverkning av extracellulära vesiklar Cellevate AB SEK 4 963 863 Completed 2021-04481
Soft Sensors for In-line Real-Time Monitoring of Critical Quality Attributes in Bioproduction Linköpings universitet SEK 5 000 000 Completed 2019-00130
Multispecific antibodies to improved efficacy and safety and to reduce costs for CNS immunotherapy Uppsala universitet SEK 9 998 600 Completed 2019-00106
New strategies for targeted payload delivery using small engineered scaffold proteins Kungliga Tekniska Högskolan SEK 9 775 000 Completed 2019-00104
AAVNova Kungliga Tekniska Högskolan SEK 10 000 000 Completed 2019-00103
CARdiac Mesenchymal Extracellular Vesicles (CARMEV) for prevention of ischemic heart failure Uppsala universitet SEK 4 188 578 Completed 2019-00129
Development and formulation centre for next generation biologics RISE Research Institutes of Sweden AB SEK 36 000 000 Completed 2018-04730
Encapsulated cell-based delivery of biologics to the brain for targeted therapies of neurodegenerative disorders Sinfonia Biotherapeutics AB SEK 4 154 995 Completed 2017-03001
Engineering of nano-sized membrane-vesicles for intracellular delivery of therapeutic antibodies Kungliga Tekniska Högskolan SEK 4 538 000 Completed 2017-02999
A new class of modality selective antagonistic TRPV1 antibodies for pain treatment Oblique Therapeutics AB SEK 5 000 000 Completed 2017-02993
Biologics targeting T-cells for immune modulation Karolinska Institutet SEK 4 833 488 Completed 2017-02989
Production Platform for Personalized Tissue-Engineered Transplants RISE Research Institutes of Sweden AB SEK 5 000 000 Completed 2017-02983
Novel production technologies for next generation microbial pharmaceutical products METABOGEN AB SEK 4 902 800 Completed 2017-02964
Utilization of extracellular vesicles as carriers/ vehicle of biological substances to cells and organs Göteborgs Universitet SEK 5 000 000 Completed 2017-02960

Last updated 13 July 2021